PE20151163A1 - Derivados de imidazopiridazina como moduladores del receptor gabaa - Google Patents
Derivados de imidazopiridazina como moduladores del receptor gabaaInfo
- Publication number
- PE20151163A1 PE20151163A1 PE2015000912A PE2015000912A PE20151163A1 PE 20151163 A1 PE20151163 A1 PE 20151163A1 PE 2015000912 A PE2015000912 A PE 2015000912A PE 2015000912 A PE2015000912 A PE 2015000912A PE 20151163 A1 PE20151163 A1 PE 20151163A1
- Authority
- PE
- Peru
- Prior art keywords
- gabaa receptor
- receptor modulators
- derivatives
- imidazopyridazine derivatives
- imidazopyridazine
- Prior art date
Links
- 150000005233 imidazopyridazines Chemical class 0.000 title abstract 3
- 102000027484 GABAA receptors Human genes 0.000 title abstract 2
- 108091008681 GABAA receptors Proteins 0.000 title abstract 2
- DYPBSSSLPCNNAT-UHFFFAOYSA-N 4-(3-phenylphenyl)-5h-imidazo[4,5-c]pyridazine Chemical class C1=NN=C2NC=NC2=C1C(C=1)=CC=CC=1C1=CC=CC=C1 DYPBSSSLPCNNAT-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Abstract
La invencion se refiere a derivados de imidazopiridazina. Particularmente, se refiere a derivados de 4-(bifenil-3-il)-7H-imidazo[4,5-c]piridazina de la Formula (I): donde R1 y R2 son -CH2-CH2-, -N(NH3)-CH2; R3 es H, F, CN, etc; R4 es H, F, Cl; R5 es (C2-C4)alquilo. Los derivados de imidazopiridazina de la presente invencion modulan la actividad del receptor GABAA. Son utiles para el tratamiento de diversas afecciones, por ejemplo, el dolor
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737157P | 2012-12-14 | 2012-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151163A1 true PE20151163A1 (es) | 2015-08-14 |
Family
ID=49880883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000912A PE20151163A1 (es) | 2012-12-14 | 2013-12-04 | Derivados de imidazopiridazina como moduladores del receptor gabaa |
Country Status (43)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6491679B2 (ja) * | 2014-06-12 | 2019-03-27 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体 |
| BR112016030863B1 (pt) | 2014-07-31 | 2021-05-04 | Basf Se | processo para a preparação de um composto e compostos |
| ES2882543T3 (es) | 2015-05-11 | 2021-12-02 | Basf Se | Proceso para la preparación de 4-amino-piridazinas |
| JP2018536677A (ja) * | 2015-12-10 | 2018-12-13 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | てんかんおよび疼痛の治療において使用するための、ＧＡＢＡ受容体モジュレーターとしての式（Ｉ）の４−（ビフェン−３−イル）−１Ｈ−ピラゾロ［３，４−ｃ］ピリダジン誘導体 |
| CA3033249A1 (en) * | 2016-09-23 | 2018-03-29 | Novartis Ag | Indazole compounds for use in tendon and/or ligament injuries |
| JOP20190053A1 (ar) * | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
| EP3619213A1 (de) | 2017-05-02 | 2020-03-11 | Bayer Aktiengesellschaft | 2-(het)aryl-substituierte kondensierte heterocyclen-derivate als schädlingsbekämpfungsmittel |
| EP4410295A3 (en) * | 2017-06-06 | 2024-10-16 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
| WO2019226820A1 (en) * | 2018-05-22 | 2019-11-28 | Neurocycle Therapeutics, Inc. | Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis |
| TWI752400B (zh) * | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| CN120865250A (zh) | 2022-02-25 | 2025-10-31 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
| CN117069725A (zh) * | 2022-05-10 | 2023-11-17 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途 |
| CN116655475B (zh) * | 2023-05-19 | 2024-12-31 | 山东轩鸿生物医药有限公司 | 一种盐酸氟西汀的制备方法 |
| WO2025137437A1 (en) | 2023-12-21 | 2025-06-26 | Pfizer Inc. | Solid forms of a gabaa receptor modulator and methods of its use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6365589B1 (en) * | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
| ES2251518T3 (es) | 2000-11-10 | 2006-05-01 | MERCK SHARP & DOHME LTD. | Derivados de imidazo-triazina como ligandos para receptores gaba. |
| GB0117277D0 (en) | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| CA2555263A1 (en) * | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| EP1838152A2 (en) | 2005-01-21 | 2007-10-03 | Neurogen Corporation | Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives |
| EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
| CA2681572C (en) | 2007-03-23 | 2014-02-11 | Icagen, Inc. | Inhibitors of ion channels |
| HRP20150355T1 (hr) | 2009-01-12 | 2015-06-19 | Pfizer Limited | Sulfonamidni derivati |
| EP2493889B1 (en) * | 2009-10-30 | 2017-09-06 | Janssen Pharmaceutica, N.V. | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| EP2590957B1 (en) * | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
-
2013
- 2013-04-12 UA UAA201504677A patent/UA112028C2/uk unknown
- 2013-12-04 RS RS20160986A patent/RS55307B1/sr unknown
- 2013-12-04 GE GEAP201313849A patent/GEP201706710B/en unknown
- 2013-12-04 EA EA201590761A patent/EA025635B1/ru not_active IP Right Cessation
- 2013-12-04 CN CN201380065006.0A patent/CN104837843B/zh active Active
- 2013-12-04 MX MX2015007598A patent/MX366023B/es active IP Right Grant
- 2013-12-04 BR BR112015014097-1A patent/BR112015014097B1/pt active IP Right Grant
- 2013-12-04 CU CUP2015000058A patent/CU24338B1/es unknown
- 2013-12-04 EP EP13812165.2A patent/EP2938615B1/en active Active
- 2013-12-04 AU AU2013356894A patent/AU2013356894B2/en active Active
- 2013-12-04 KR KR1020157017073A patent/KR101746314B1/ko active Active
- 2013-12-04 HR HRP20161559TT patent/HRP20161559T1/hr unknown
- 2013-12-04 HU HUE13812165A patent/HUE032400T2/hu unknown
- 2013-12-04 MD MDA20150051A patent/MD4651B1/ro not_active IP Right Cessation
- 2013-12-04 ES ES13812165.2T patent/ES2608640T3/es active Active
- 2013-12-04 JP JP2015547219A patent/JP5869740B2/ja active Active
- 2013-12-04 PL PL13812165T patent/PL2938615T3/pl unknown
- 2013-12-04 MA MA38112A patent/MA38112B1/fr unknown
- 2013-12-04 DK DK13812165.2T patent/DK2938615T3/da active
- 2013-12-04 PT PT138121652T patent/PT2938615T/pt unknown
- 2013-12-04 WO PCT/IB2013/060631 patent/WO2014091368A1/en not_active Ceased
- 2013-12-04 AP AP2015008526A patent/AP2015008526A0/xx unknown
- 2013-12-04 SG SG11201503735YA patent/SG11201503735YA/en unknown
- 2013-12-04 SI SI201330382T patent/SI2938615T1/sl unknown
- 2013-12-04 ME MEP-2016-258A patent/ME02566B/me unknown
- 2013-12-04 PE PE2015000912A patent/PE20151163A1/es not_active Application Discontinuation
- 2013-12-04 CA CA2892174A patent/CA2892174C/en active Active
- 2013-12-04 LT LTEP13812165.2T patent/LT2938615T/lt unknown
- 2013-12-11 TW TW102145600A patent/TWI478926B/zh active
- 2013-12-12 AR ARP130104648A patent/AR093937A1/es unknown
- 2013-12-12 UY UY35185A patent/UY35185A/es unknown
- 2013-12-12 US US14/103,960 patent/US8952008B2/en active Active
-
2014
- 2014-12-19 US US14/576,796 patent/US20150105396A1/en not_active Abandoned
-
2015
- 2015-05-14 CR CR20150254A patent/CR20150254A/es unknown
- 2015-05-29 US US14/725,234 patent/US20150259352A1/en not_active Abandoned
- 2015-06-04 IL IL239243A patent/IL239243A0/en active IP Right Grant
- 2015-06-05 PH PH12015501293A patent/PH12015501293B1/en unknown
- 2015-06-09 TN TNP2015000261A patent/TN2015000261A1/fr unknown
- 2015-06-11 NI NI201500081A patent/NI201500081A/es unknown
- 2015-06-11 ZA ZA2015/04226A patent/ZA201504226B/en unknown
- 2015-06-12 CL CL2015001652A patent/CL2015001652A1/es unknown
- 2015-06-12 DO DO2015000147A patent/DOP2015000147A/es unknown
- 2015-07-11 EC ECIEPI201529822A patent/ECSP15029822A/es unknown
- 2015-08-04 GT GT201500159A patent/GT201500159A/es unknown
-
2016
- 2016-12-05 CY CY20161101251T patent/CY1118568T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151163A1 (es) | Derivados de imidazopiridazina como moduladores del receptor gabaa | |
| UY35012A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| CR20110610A (es) | Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades | |
| DOP2016000041A (es) | Compuestos derivados de 5,5,7,7-tetrametil-5,7-dihidro-4h-tieno[2,3-c]piran-3-carboxamida que son moduladores del regulador de la conductancia transmembrana de la fibrosis quística (cftr) | |
| UY35409A (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| ECSP13012958A (es) | Inhibidores de benzodioxano de la producción de leucotrieno. | |
| AR095823A1 (es) | Compuesto de ciclopropanamina y uso del mismo | |
| CR20140166A (es) | Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1 | |
| UY35155A (es) | Derivados cíclicos de nucleósidos y usos de los mismos | |
| CR20150171A (es) | Benzamidas | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| PE20200387A1 (es) | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer | |
| MX2013012211A (es) | Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato. | |
| CR20140435A (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| UY32747A (es) | 2-carboxamida-cicloamino-ureas sustituidas | |
| CU20150050A7 (es) | Derivados de oxazolidin-2-ona-pirimidina | |
| DOP2015000007A (es) | Métodos para preparar triazolopiridinas sutituidas | |
| CU20150015A7 (es) | Tris-(hetero)aril-pirazoles y su uso | |
| CR11436A (es) | Moduladores enlazados a amida y-secretasa | |
| CR20150068A (es) | Ciclopentilpirazoles como bloqueadores del canal de calcio tipo n | |
| BR112012022096A2 (pt) | 6-aminoindolinas catiônicas, composições corantes contendo as mesmas, seus processos e utilizações. | |
| CO2022002022A2 (es) | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias | |
| CR11644A (es) | Tratamiento para desordenes relacionados con los ojos | |
| GT201400058A (es) | Composición para ser aplicada a la piel, y uso de la misma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |